Semetkowska-Jurkiewicz E, Milewski J, Krupa-Wojciechowska B, Wójcikowski C, Horoszek-Maziarz S
II Kliniki Chorób Wewnetrznych Instytutu Chorób Wewnetrznych AM, Gdańsku.
Pol Tyg Lek. 1993;48(1-2):19-21, 26.
The studies included 18 normotensive patients with diabetes mellitus type I (mean age 29 years) and constant microalbuminuria (UAE-30 - 300 mg/24 hours). Group A consisted of 10 patients treated with enalapril, and group B--10 patients given placebo. Glomerular filtration rate, ERPF, and UAE were measured before and after 6 months of therapy. UAE decreased significantly in patients of group A (p = 0.02) after 6 months while evident proteinuria was seen in two patients of group B. Arterial blood pressure dropped in patients of group A (131/84 vs 122/78 mm Hg), and increased significantly in patients of group B (126 +/- 8 vs 136 +/- 15 mm Hg; p < 0.05). Blood flow through kidneys improved (p = 0.02) and renal vascular resistance decreased (p = 0.02) in patients of group A. The obtained results suggest that enalapril may prevent diabetic nephropathy in diabetics with constant microalbuminuria.
这些研究纳入了18例I型糖尿病血压正常患者（平均年龄29岁），伴有持续性微量白蛋白尿（尿白蛋白排泄率为30 - 300mg/24小时）。A组由10例接受依那普利治疗的患者组成，B组为10例给予安慰剂的患者。在治疗6个月前后测量肾小球滤过率、有效肾血浆流量和尿白蛋白排泄率。6个月后，A组患者的尿白蛋白排泄率显著降低（p = 0.02），而B组有2例患者出现明显蛋白尿。A组患者的动脉血压下降（131/84 vs 122/78 mmHg），B组患者的动脉血压显著升高（126±8 vs 136±15 mmHg；p < 0.05）。A组患者的肾血流量改善（p = 0.02），肾血管阻力降低（p = 0.02）。所获结果提示，依那普利可能预防持续性微量白蛋白尿糖尿病患者发生糖尿病肾病。
